Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY D52005-P56905 For Against Abstain APREA THERAPEUTICS, INC. APREA THERAPEUTICS, INC. 535 BOYLSTON STREET BOSTON, MA 02116 1a. Oren Gilad, Ph. D. 1b. John B. Henneman III 1c. Christian S. Schade The Board of Directors recommends a vote FOR all the nominees listed in Proposal 1, FOR all of the directors listed in Proposal 2 and FOR Proposals 3, 4, 5 and 6. 1. ELECTION OF THREE CLASS III DIRECTORS Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title. ! ! ! VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. During The Meeting - Go to www.virtualshareholdermeeting.com/APRE2022 You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postagepaid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. 3. To approve the issuance, in accordance with Nasdaq Listing Rule 5635(a), of the Company's common stock, upon conversion of the Copany's Series A Preferred Stock issued on May 16, 2022 4. To approve the amendments to the Company's Amended and Restated Certificate of Incorporation, to effect a reverse stock split at a ratio in the range of 1-for-3 to 1-for-20, inclusive, with the exact ratio to be set within that range at the discretion of the Board of Directors 5. To approve the amendment of the Aprea Therapeutics, Inc. 2019 Equity Incentive Plan to increase the number of shares authorized for issuance by 2,000,000 shares 6. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022 ! ! ! ! ! ! 2. THE RATIFICATION, ON AN ADVISORY BASIS, OF THE APPOINTMENTS OF CLASS I AND CLASS II DIRECTORS 2a. Marc Duey (Class I) 2b. Michael Grissinger (Class II) 2c. Rifat Pamukcu, M.D.(Class II) For Withhold ! ! ! For Against Abstain ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! PRELIMINARY -- SUBJECT TO COMPLETION |